About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 637 record(s)
Req # A-2022-001494
The draft Product Monograph included in the New Drug Submission (NDS) for Captopril at the time of screening, any and all Notices of Deficiency, Notices of Non-Compliance and clarifaxes associated with Health Canada's review of the NDS.Organization: Health Canada
May 2023
Req # A-2022-001499
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24 for the medicinal ingredient aprepitant. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for aprepitant which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24.Organization: Health Canada
May 2023
Req # A-2022-001505
A list of all drug manufacturing plants currently banned from producing drugs for the Canadian market. Please include the reason for the ban, the location of the plant and the name of the company running the plant.Organization: Health Canada
May 2023
Req # A-2022-001509
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24 for the medicinal ingredients methotrexate & methotrexate sodium. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for methotrexate & methotrexate sodium which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24.Organization: Health Canada
May 2023
Req # A-2022-001590
Details regarding all proceedings, applications or remedies currently active, ongoing or pending, or any balance of money owed to you by these corporations: Gestion RCM Modulaire Inc. (NEQ: 1171125736), 28 Industrielle Street, Québec City QC G0M 1P0. R.C.M. MODULAIRE INC. (NEQ: 1149510068), 28 Industrielle Street, Québec City QC G0M 1P0. Location RCM Inc. (NEQ: 1169281483), 28 Industrielle Street, Québec City QC G0M 1P0.Organization: Health Canada
May 2023
Req # A-2022-001609
Obtain a copy of any document regarding the corporation, in its capacity as an owner or tenant of the building located at. Corporation: ÉLITE CHRYSLER JEEP INC. NEQ: 1162705215. Building address: 6138 De Saint-Élie Road, Sherbrooke QC J1R 0L1 Canada. Cadastre: 3195210. Owners: Immeubles Bilodeau Dallaire Inc.Organization: Health Canada
May 2023
Req # A-2023-000017
Any information on Notice of Compliances issued to a second person prior to the expiry of a patent on the patent register due to successful litigation under the Patented Medicines Regulations. Particularly, any Notice of Compliance granted under sections 7(1)(b), (c), and (d) of the Regulations. All Notices since 2011.Organization: Health Canada
May 2023
Req # A-2023-000018
A list of patents for which a Notice of Allegation under sections 5(2.1)(c)(ii), (iii), and (iv) of the Patented Medicines (Notice of Compliance) Regulations was filed. Requesting all Notices since 2011.Organization: Health Canada
May 2023
Req # A-2023-000019
Obtain certain information regarding the file status of these businesses with your organization. Business: Centre de traitement de la biomasse de la Montérégie Inc. (NEQ: 1173286908) 1265 Grand rang Saint-François, Saint-Pie QC J0H 1W0. Business: Qarbonex Services Inc. (NEQ: 1171667497) 1265 Grand rang Saint-François, Saint-Pie QC J0H 1W0.Organization: Health Canada
May 2023
Req # A-2023-000028
All internal reports or briefing notes generated in Health Canada that reference the cluster of patients with a potential neurological syndrome of unknown cause in New Brunswick that were published between February 1, 2022 and March 1, 2023.Organization: Health Canada
May 2023